On September 7, 2020 THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics reported that it will publish its consolidated half-year results closed on June 30, 2020 and approved by the Board of Directors on September 17, 2020, Monday September 21, 2020 at 5:45 p.m. CEST (Paris time) (Press release, Theradiag, SEP 7, 2020, View Source [SID1234564701]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bertrand de Castelnau, Chief Executive Officer, will present these half-year results during a conference call on Tuesday, September 22, 2020, at 9:00 a.m. Paris time, and will answer questions from analysts and investors.

To access the conference call , please dial 01.72.72.74.03, followed
by the access code 24 52 93 51 #. To access the slideshow by internet , click on the following link: https: //www.anywhereconference.comConference=418950313&PIN=24529351&UserAudioMode=DATA .

The presentation will also be made available on the company’s website: View Source

The replay will also be available for a period of 90 days by dialing: 01 70 71 01 60 followed by the access code: 41 89 50 313 # then follow the instructions.

Next financial event in which Theradiag is participating:

-1 st October 2020: Seminar Health / Biotech – Portzamparc BNP Paribas Digital Format